Guttman-Yassky, E. , Weidinger, S. , Simpson, E. , Gooderham, M. , Irvine, A. , Spelman, L. , Silverberg, J. , Elmaraghy, H. , DeLuca-Carter, L. , Buziqui Piruzeli, M.L. , Hu, C. , Yang, F.E. , Pierce, E. , Bardolet, L. and Thaci, D. 2023. Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s271. DOI:https://doi.org/10.25251/skin.7.supp.271.